ATE327004T1 - Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 - Google Patents
Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40Info
- Publication number
- ATE327004T1 ATE327004T1 AT01977428T AT01977428T ATE327004T1 AT E327004 T1 ATE327004 T1 AT E327004T1 AT 01977428 T AT01977428 T AT 01977428T AT 01977428 T AT01977428 T AT 01977428T AT E327004 T1 ATE327004 T1 AT E327004T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- antigen
- antibody
- therapy
- binding fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 101150013553 CD40 gene Proteins 0.000 title 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 5
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 4
- 108010063916 CD40 Antigens Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 230000003211 malignant effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23755600P | 2000-10-02 | 2000-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE327004T1 true ATE327004T1 (de) | 2006-06-15 |
Family
ID=22894238
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01977428T ATE327004T1 (de) | 2000-10-02 | 2001-10-02 | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 |
| AT01979395T ATE489403T1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 |
| AT06005656T ATE541860T1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 zur therapie von b- zell tumoren |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01979395T ATE489403T1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 |
| AT06005656T ATE541860T1 (de) | 2000-10-02 | 2001-10-02 | Humane antikörper gegen cd40 zur therapie von b- zell tumoren |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7288252B2 (enExample) |
| EP (3) | EP1326896B1 (enExample) |
| JP (6) | JP4202127B2 (enExample) |
| AT (3) | ATE327004T1 (enExample) |
| AU (4) | AU2001296545A1 (enExample) |
| CA (2) | CA2424296A1 (enExample) |
| DE (2) | DE60143535D1 (enExample) |
| ES (1) | ES2357051T3 (enExample) |
| PT (1) | PT1326896E (enExample) |
| WO (4) | WO2002028905A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US7288252B2 (en) * | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| ATE374214T1 (de) | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| ATE476448T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung |
| CA2544852A1 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| US20070110754A1 (en) * | 2003-11-04 | 2007-05-17 | Chiron Corporation | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
| JP4810431B2 (ja) * | 2003-11-04 | 2011-11-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｂ細胞に関連する癌に対する治療方法 |
| WO2005044855A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| US7939642B2 (en) | 2005-04-09 | 2011-05-10 | Fusion Antibodies Limited | Antibody and uses thereof |
| US8337851B2 (en) * | 2005-05-18 | 2012-12-25 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer |
| DK1889065T3 (da) * | 2005-05-18 | 2013-09-02 | Xoma Technology Ltd | Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent |
| EP1945260B1 (en) * | 2005-11-01 | 2012-10-24 | Novartis AG | Uses of anti-cd40 antibodies |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| WO2007130493A2 (en) | 2006-05-03 | 2007-11-15 | Regents Of The University Of Colorado | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| CA2705263A1 (en) * | 2007-11-09 | 2009-05-14 | Novartis Ag | Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies |
| AU2009206506B2 (en) * | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
| US9102734B2 (en) | 2009-03-10 | 2015-08-11 | Baylor Research Institute | Fusion proteins comprising antibody and HPV E6 and E7 antigens |
| MX2011009439A (es) | 2009-03-10 | 2013-06-18 | Baylor Res Inst | Vacunas con especificidad de objetivo hacia celula presentadora de antigeno. |
| WO2010104761A2 (en) | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| EP4450523A3 (en) | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| CA3122934C (en) | 2011-03-11 | 2025-09-02 | Beth Israel Deaconess Medical Center, Inc. | Fusion protein comprising a CD40 fragment and production method |
| CA2831294A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
| AU2012245309C1 (en) | 2011-04-21 | 2016-07-21 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| WO2013072523A1 (en) * | 2011-11-17 | 2013-05-23 | Gundram Jung | Bi-specific antibodies for medical use |
| JP2016011258A (ja) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 |
| JP6475631B2 (ja) | 2012-11-19 | 2019-02-27 | バリオファルム・アクチェンゲゼルシャフト | Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体 |
| US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| WO2016069919A1 (en) | 2014-10-29 | 2016-05-06 | Seattle Genetics, Inc. | Dosage and administration of non-fucosylated anti-cd40 antibodies |
| JP6830437B2 (ja) | 2014-12-10 | 2021-02-17 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 疾患を処置するための遺伝子改変された細胞、組織および臓器 |
| CN107810198B (zh) | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
| CR20180177A (es) * | 2015-09-30 | 2018-06-22 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso |
| ES2963807T3 (es) | 2016-06-08 | 2024-04-02 | Xencor Inc | Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EA201990293A1 (ru) | 2016-07-14 | 2019-07-31 | Генмаб А/С | Мультиспецифичные антитела против cd40 и cd137 |
| JP2020513554A (ja) | 2016-12-07 | 2020-05-14 | プロジェニティ， インコーポレイテッド | 胃腸管の検出方法、装置およびシステム |
| EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| JP7257971B6 (ja) | 2017-06-01 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| CA3120619A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP3892634A4 (en) | 2018-11-30 | 2022-11-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF |
| JP2022513671A (ja) | 2018-11-30 | 2022-02-09 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｃｄ４０抗体医薬品組成物およびその使用 |
| NL2022494B1 (en) * | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| JP2022519082A (ja) * | 2019-02-01 | 2022-03-18 | ラヴァ・セラピューティクス・ベー・フェー | 新規ｃｄ４０結合抗体 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| JP2023505168A (ja) | 2019-12-03 | 2023-02-08 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インターフェロン会合抗原結合タンパク質及びこれらの使用 |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| AU2022233547A1 (en) | 2021-03-09 | 2023-09-28 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in therapy |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| BR112023023291A2 (pt) | 2021-05-07 | 2024-01-30 | Chris Kalinski | Avaliação de probabilidade de risco para operações de envio de carga e métodos de uso |
| MX2023015070A (es) * | 2021-06-28 | 2024-01-17 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| CN117500816B (zh) | 2021-08-26 | 2025-03-28 | 映恩生物制药（苏州）有限公司 | 一种甾体化合物及其缀合物 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023401158A1 (en) | 2022-12-01 | 2025-05-29 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US59427A (en) * | 1866-11-06 | Improvement in fences | ||
| US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
| US4355023A (en) | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4727018A (en) | 1984-05-18 | 1988-02-23 | Eichner Ronald D | Immunoregulation of transplantable tissue |
| US5068223A (en) | 1985-09-09 | 1991-11-26 | Board Of Regents, University Of Texas System | Hydrophobic peptide esters and amides |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US4923872A (en) | 1986-08-26 | 1990-05-08 | Warner-Lambert Co. | Analogues of pyrrolo[3,2d]pyrimidin-4-ones |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| ES2051726T3 (es) * | 1987-01-17 | 1994-07-01 | Asta Medica Ag | Procedimiento para preparar productos inyectables que contienen azelastin y teofilina o azelastin y beta-mimeticos. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| EP0434879A1 (en) | 1989-12-14 | 1991-07-03 | Schering-Plough | Method of making factor dependent human B cell lines |
| JPH06508501A (ja) | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
| EP0897983B1 (en) | 1991-10-25 | 2003-05-07 | Immunex Corporation | Antibody against CD40-L |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| CA2139571C (en) | 1992-07-07 | 2006-11-14 | Eleanor N. Fish | Interferon receptor binding peptides |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| EP1834671A3 (en) * | 1992-07-09 | 2013-05-22 | Novartis Vaccines and Diagnostics, Inc. | A method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| EP0724456B1 (en) | 1993-10-01 | 2003-12-10 | Immunex Corporation | Antibodies to cd40 |
| WO1995017202A1 (en) | 1993-12-23 | 1995-06-29 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 |
| WO1996034096A1 (en) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1221973B1 (en) * | 1999-10-04 | 2007-05-30 | Novartis Vaccines and Diagnostics, Inc. | CD40 antagonist for treating psoriasis |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| AU1590201A (en) | 1999-11-09 | 2001-06-06 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US7288252B2 (en) * | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
-
2001
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 DE DE60143535T patent/DE60143535D1/de not_active Expired - Lifetime
- 2001-10-02 ES ES01979395T patent/ES2357051T3/es not_active Expired - Lifetime
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 AT AT01977428T patent/ATE327004T1/de not_active IP Right Cessation
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en not_active Ceased
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/ja not_active Expired - Fee Related
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en not_active Ceased
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en not_active Ceased
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en not_active Ceased
- 2001-10-02 AT AT01979395T patent/ATE489403T1/de active
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/ja not_active Expired - Lifetime
- 2001-10-02 PT PT01979395T patent/PT1326896E/pt unknown
- 2001-10-02 EP EP01979395A patent/EP1326896B1/en not_active Expired - Lifetime
- 2001-10-02 EP EP06005656A patent/EP1717251B1/en not_active Expired - Lifetime
- 2001-10-02 DE DE60119945T patent/DE60119945T2/de not_active Expired - Lifetime
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 EP EP01977428A patent/EP1322383B9/en not_active Expired - Lifetime
- 2001-10-02 AT AT06005656T patent/ATE541860T1/de active
-
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/ja active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/ja active Pending
-
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/ja not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
-
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/ja active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
-
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE327004T1 (de) | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 | |
| CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| WO2005044304A3 (en) | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia | |
| ATE212038T1 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
| CY1110874T1 (el) | Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας | |
| DK2853272T3 (da) | Terapeutisk anvendelse af anti-CS1-antistoffer | |
| DK1684869T3 (da) | Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme | |
| TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
| BR0315140A (pt) | Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação | |
| WO2004019991A3 (en) | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma | |
| NZ329403A (en) | Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |